DiscoveryBioMed Receives $1.35 Million SBIR Award from the National Institutes of Health (NIH) to Continue Its Cystic Fibrosis Drug Discovery Program

BIRMINGHAM, Ala.--(BUSINESS WIRE)--DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH. The two-year award will focus on validation and prioritization of several lead CFCL chemical classes, drugs that correct the most common cystic fibrosis (CF) disease-causing mutation.

Back to news